Skip to content
OpenCapital
Get started

King Pharmaceuticals KG Underwriting Income Loss Net

Discontinued — last reported Q3 '25

Segments

By segment

See full
Legacy Reinsurance-$3.28M—

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M—
Total equity$121.4M+2,773%
Total assets$964.2M—

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×—
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%—

Returns & leverage

See full
Return on equity90.8%—
Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept kg:UnderwritingIncomeLossNet.

The official record: King Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's underwriting income loss net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's underwriting income loss net?
King Pharmaceuticals (KG) reported underwriting income loss net of -$8.02M in Q3 2025.